奥扎格雷-脑得生序贯治疗急性脑梗死的前瞻性的药物经济学研究△.docVIP

PAGE PAGE 2 △[基金项目]本研究为贵州省卫生厅科学技术基金项目科研课题（项目编号：D-234） ﹡[作者简介]：王玉和，男，教授，主任药师，硕士研究生导师；从事医院药学及药物经济学。TelE-mail: HYPERLINK mailto:wangyuhe11@163.com wangyuhe11@163.com， 奥扎格雷-脑得生序贯治疗急性脑梗死的前瞻性的药物经济学研究△ 王玉和1﹡，余昌胤2，张骏2，雷显泽2，余 娜 2，周 妮2 （1.遵义医学院药学院药剂教研室 ；2.遵义医学院附属医院神经内科，贵 州 遵 义 563003） 摘要：目的：探讨奥扎格雷-脑得生序贯治疗急性脑梗死的安全性﹑有效性并对两组的医疗费用进行药物经济学评价。方法：采用前瞻性的随机临床对照试验研究，共入选278例急性脑梗死患者，进入符合方案分析集（PPS）的264例，随机分为两组，每组各132例；试验A组（以下简称A组），采用奥扎格雷80mg，ivgtt，bid，14天后改用脑得生口服，一次6粒，一日3次至28天；对照B组（以下简称B组），采用奥扎格雷80mg，ivgtt，bid，28天。两组基础治疗相同。治疗结束后对两组患者进行神经功能缺损评分（ESS）和日常生活能力评分（ADL）同时进行临床疗效及安全性比较。并且运用药物经济学的最小成本分析法、成果—效果分析法推算每例治疗成本并进行分析评价。结果：两组临床基本痊愈率和总有效率分别为31.8%、96.2%和31.1％、96.9％，不良反应发生率分别为5.8%和7.1%。基本治愈每例病人所需药品的最小成本20701元和40839元；以临床总有效率计C/E分别为141.8和205.4；ΔC/ΔE为894000。结论：两组临床疗效相近，而费用有显著性差异；奥扎格雷连续静脉滴注组中药品费用较高，奥扎格雷-脑得生序贯治疗急性脑梗死组更具成本—效果优势。 关键词：急性脑梗死；奥扎格雷；脑得生胶囊；序贯治疗；药物经济学；最小成本分析法；成本—效果分析法；随机对照试验。 The Prospective Randomized Clinic Test Research of Ozagrel-Naodesheng Sequential Antimicrobial Therapy in Curing Acute Cerebral Infarction△ Wang Yuhe1﹡, Yu Changyin2, Zhang Jun2, Lei Xianze2, Yu Na2, Zhou Ni2 (1. pharmaceutics department of college of pharmacy of Zunyi medical college; 2. Nerve Medical Department of the affiliated hospital of Zunyi medical college Zunyi, Guizhou Abstract Objective: To estimate the safety and validity Ozagrel-Naodesheng Sequential antimicrobial therapy in curing acute cerebral infarction. Methods: It used prospective randomized controlled design of experiment, and then 278 patients of acute cerebral infarction were selected. The numbers of patients who fitted for program were 264, which were divided into two groups: group A and group B. Each group was 132 samples. Group A was administered with Ozagrel 80mg twice a day. After fourteen days Naodesheng was taken in 14 days , 6 pills each time , third times per day. Group B: Ozagrel 80mg was administered with Ozagrel 80mg twice a day for 28 days. The basic therapy of two groups were same.